The psychopharmacology of European herbs with cognition-enhancing properties

Current Pharmaceutical Design

Volumn 12, Issue 35, 2006, Pages 4613-4623

  Kennedy, David O ^a   Scholey, Andrew B ^a  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

Cognition; Dementia; Melissa officinalis; Memory; Mood; Rosmarinus officinalis; Salvia lavandulaefolia; Salvia officinalis

Indexed keywords

ACETYLCHOLINESTERASE; ARECOLINE; ATROPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; ESSENTIAL OIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HEXOBARBITAL; HUPERZINE A; HUPERZINE B; HYOSCYAMINE; MELISSA OFFICINALIS EXTRACT; MUSCARINE; MUSCARINIC RECEPTOR; NICOTINIC AGENT; NICOTINIC RECEPTOR; PHYSOSTIGMINE; PILOCARPINE; PLACEBO; PLANT EXTRACT; ROSMARINUS OFFICINALIS EXTRACT; SALVIA LAVANDULAEFOLIA; SALVIA OFFICINALIS EXTRACT; SCOPOLAMINE; UNINDEXED DRUG;

AGING; AGITATION; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AROMATHERAPY; BRAIN TISSUE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG RESEARCH; DRUG TOLERABILITY; ENZYME INHIBITION; ESTROGEN ACTIVITY; EUROPE; EXTRACTION; HERB; HUMAN; LONG TERM CARE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; AROMATHERAPY; BEHAVIOR; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; COGNITION; EUROPE; HUMANS; MELISSA; NOOTROPIC AGENTS; PHYTOESTROGENS; PLANT EXTRACTS; PLANTS, MEDICINAL; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CHOLINERGIC; ROSMARINUS; SALVIA OFFICINALIS;

EID: 33751538587     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206779010387     Document Type: Review

References (91)

1. Mantle D, Pickering AT, Perry EK. Medicinal plant extracts for the treatment of dementia. A review of their pharmacology, efficacy and tolerability. CNS Drugs 2000; 13: 201-213.
2. Perry N, Court G, Bidet N, Court J, Perry E. European Herbs with cholinergic activities: potential in dementia therapy. Int J Geriatr Psychiatry 1996; 11: 1063-1069.
3. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NSL. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol 1999; 51: 527-534.
4. Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol 2000; 69: 105-114.
5. Grutzlender J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61: 41-52.
6. Amenta F, Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches. Mech Ageing Dev 2001; 122: 2025-2040.
7. Rivera D, Obon C, Cano R. The botany, history and traditional uses of Three-lobed Sage (Salvia Fruticosa Miller)(Labiatae). Econ Bot 1994; 48: 190-195.
8. Ryman D. Aromatherapy. Judy Piakus Publishers, London 1991.
9. MacKintyre A. The Complete Floral Healer. Gaia Books Ltd. London 1996.
10. Hsu HY, Chen YP. Oriental Materia Medica: a concise guide. Oriental Healing Arts Institute. Long Beach, CA 1986.
11. Grieve M. A Modern Herbal. Jonathan Cape. London 1931.
12. Valnet J. Aromatherapie. Maloine. S.A. Publishers. Paris 1990.
13. Crellin JK, Philpott J. Herbal Medicine: Past and Present (Vol II), Duke University Press. London 1990.
14. Blumenthal M. (Ed) The Complete German Commission E monographs. Integrative Medicine Communications. Boston MA 1998.
15. Bartram T. Bartram's Encyclopedia of Herbal Medicine. Robinson, London 1998.
16. British Herbal Pharmacopoeia. British Herbal Medicine Association, Bournemouth 1983.
17. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients. John Wiley, Chichester 1996.
18. Perry NSL, Houghton PJ, Sampson J, Theobald AE, Har S, Lis-Balchin M, et al. In vitro activities of S. lavandulaefolia (Spanish Sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol 2001; 53: 1347-1356.
19. Hohmann J, Zupko I, Redei D, Csanyi M, Falkay G, Mathe I, et al. Protective effects of the aerial parts of Salvia Officinalis, Melissa Officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med 1999; 65: 576-578.
20. Price, S. Aromatherapy Workbook. Harper Collins, London 1998.
21. Perry NSL, Houghton PJ, Theobald A, Jenner P, Perry EK. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 2000; 52: 895-902.
22. Perry NSL, Houghton PJ, Jenner P, Keith A, Perry EK. Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine 2002; 9: 48-51.
23. Miyazawa M, Watanabe H, Kameoka H. Inhibition of acetylcholinesterase activity by monoterpenoids with a p-menthane skeleton. J Agric Food Chem 1997; 45: 677-679.
24. Miyazawa M, Watanabe H, Umemoto K, Kameoka H. Inhibition of acetylcholinesterase activity by essential oils of mentha species. J Agric Food Chem 1998; 46: 3431-3434.
25. Savelev S, Okello E, Perry NSL, Wilkins RM, Perry E. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav 2003; 75: 661-668.
26. Tildesley NTJ, Kennedy DO, Perry EK, Ballard C, Savelev S, Wesnes KA, et al. Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 2003; 75: 669-674.
27. Tildesley NTJ, Kennedy DO, Perry EK, Ballard C, Wesnes KA, Scholey AB. Cognitive and mood effects of acute administration of Salvia lavandulaefolia (Spanish Sage) to healthy young volunteers. Physiol Behav 2004. In Press
28. Scholey AB, Tildesley NTJ, Kennedy DO, Perry EK, Ballard C, Wesnes KA. Modulation of Cognitive Performance following Acute Administration of Salvia officinalis (sage) in healthy older volunteers: A randomised double blind, placebo controlled study. Submitted
29. Savelev SU, Okello EJ, Perry EK. Butyryl and Acetyl - cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res 2004; 18: 315-324.
30. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147.
31. Aisen PS. Inflammation and Alzheimer's disease. Mol Chem Neuropathol 1996; 28: 83-88.
32. Lamaison JL, Petitjean-Freytet C, Carnat A. Medicinal Lamiaceae with antioxidant properties, a potential source of rosmarinic acid. Pharm Acta Helv 1991; 66: 185-8.
33. Djarmati Z, Jankov RM, Djordjevic A, Ribar B, Lazar D, Engel P. Carnosic acid 12-Methyl Ether-(-lactone, a Ferruginol type diterpene from Salvia officinalis. Phytochemistry 1992; 31: 1307-1309.
34. Dorman HPJ, Deans SG, Noble RC. Evaluation in vitro of plant essential oils as natural antioxidants. J Essent Oil Res 1995; 7: 645-651.
35. Mantle D, Eddeb F, Pickering A. Comparison of relative antioxidant activities of British medicinal plant species in vitro. J Ethnopharmacol 2000b; 72: 47-51.
36. Lu Y, Foo LY. Rosmarinic acid derivatives from Salvia officinalis. Phytochemistry 1999; 51: 91-94.
37. Petersen M, Simmonds MSJ. Molecules of interest: Rosmarinic Acid Phytochemistry 2003; 62: 121-125.
38. Henderson V. Estrogen, Cognition, and a Woman's Risk of Alzheimer's Disease. Am J Med 1997; 103: 11S-18S
39. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia (Cochrane Review). In: The Cochrane Library, Issue 4, Oxford: Update Software 2002
40. Mulnard RI, Cotman CW, Kawas C, Van Dyck CA., Sano H, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease - A randomised controlled trial. J Am Med Ass 2000; 283: 1007-1015.
41. Jordan, V.C. Designer estrogens. Sci Am 1998; 279: 36-44.
42. Shepherd JE. Effects of estrogen on cognition, mood, and degenerative brain diseases. J Am Pharm Assoc 2001; 41: 221-8.
43. De Leo V, Lanzetta D, Cazzavacca R, Morgante G. Treatment of neurovegatitive menopausal symptoms with a phytotherapeutic agent. Minerva Ginecol 1998; 50: 207-211.
44. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res Rev 1996; 21: 285-300.
45. Perry NSL, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav 2003; 75: 651-659.
46. Akhondzadeh S, Noroozian N, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003; 28: 1-7.
47. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997; 278: 1327-32.
48. Grieve M. A Modern Herbal. Jonathan Cape. London 1931.
49. Kommission E Monograph, 1984; Melissenblätter; Bundesanzeiger 05.12.
50. Bisset NG, Wichtl M. Herbal Drugs. Medpharm. Stuttgart 1994
51. Wong AHC, Smith M, Boon HS Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55: 1033-1044.
52. Carnat AP, Carnat A, Fraisse D, Lamaison JL. The aromatic and Polyphenolic composition of lemon balm (Melissa Officinalis L. subsp. Officinalis) tea. Pharm Acta Helv 1998; 72: 301-305.
53. Sadraei H, Ghannadi A, Malekshahi K.Relaxant effect of essential oil of Melissa officinalis and citral on rat ileum contractions. Fitoterapia 2003; 74: 445-452.
54. Hohmann J, Zupko I, Redei D, Csanyi M, Falkay G, Mathe I, et al. Protective effects of the aerial parts of Salvia Officinalis, Melissa Officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med 1999; 65: 576-578.
55. Mulkens A, Stephanou E, Kapetenadis I. Heterosides a genines volatiles dans les feuilles de Melissa Officinalis L. (lamiaceae). Pharm Acta Helv 1985; 60: 276-278.
56. Tittel G, Wagner H, Bos R. Über die chemische Zusammensetzung von Melisseolen; Planta Med 1982; 46: 91-98.
57. Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon Balm). Pharmacol Biochem Behav 2002; 72: 953-64.
58. Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wake G, et al. Modulation of mood and cognitive performance following administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor binding properties. Neuropsychopharmacology 2003; 28: 1871-81.
59. Lamaison JL, Petitjean-Freytet C, Carnat A. Medicinal Lamiaceae with antioxidant properties, a potential source of rosmarinic acid. Pharm Acta Helv 1991; 66: 185-8.
60. Tagashira M, Ohtake Y. A new antioxidative 1, 3-benzodioxole from Melissa Officinalis. Planta Med 1998; 64: 555-558.
61. Wagner H, Sprinkmeyer L, Über die pharmakologische Wirkung von Melissengeist; Dtsch Apoth Ztg 1973; 113: 1159-66.
62. Soulimani R, Fleurentin J, Mortier F, Misslin R, Derrieu G, Pelt JM. Neurotropic action of the hydroalcoholic extract of Melissa officinalis in the mouse. Planta Medica 1991; 57: 105-109.
63. Dressing H, Riemann D, Löw H, Schredl M, Reh C, Laux P, et al. Insomnia: are valerian/balm combinations of equal value to benzodiazepine? Therapiewoche 1992; 42: 726-736.
64. Cerny A, Schmid K. Tolerability and efficacy of valerian/lemon balm in healthy volunteers: a double-blind, placebo-controlled, multicentre study. Fitoterapia 1999; 70(3): 221-228.
65. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory induced stress in humans following acute administration of Melissa officinalis (Lemon Balm). Psychosom Med 2004; 66: 607-613
66. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2003: 63(7): 553-8
67. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry 2003; 74: 863-866.
68. Le Strange, R. A History of Herbal Plants. Morrison & Gibb, London 1997.
69. ESCOP. "Rosmarini folium." Monographs on the Medicinal Uses of Plant Drugs. Exeter, U.K.: European Scientific Cooperative on Phytotherapy 1997.
70. Del Campo J. Amiot MJ. Nguyen-The C. Antimicrobial effect of rosemary extracts. J Food Prot 2000; 63(10): 1359-68.
71. Martinez-Tome M, Jimenez AM, Ruggieri S, Frega N, Strabbioli R, Murcia MA. Antioxidant properties of Mediterranean spices compared with common food additives. J Food Prot 2001; 64(9): 1412-9.
72. Saenz-Lopez R, Fernandez-Zurbano P, Tenna MT. Capillary electrophoretic separation of phenolic diterpenes from rosemary. J Chromatogr A 2002; 953: 251-256.
73. Thorsen MA, Hildebrandt KS. Quantitative determination of phenolic diterpenes in rosemary extracts: Aspects of accurate quantification. J Chromatogr A 2003; 995: 119-125.
74. Okamura N, Haraguchi H, Hashlmotot K, Yagi A. Flavonoids in Rosmarinus officinalis leaves. Phytochemistry 1994; 37: 1463-1466.
75. Justesen U, Knuthsen P. Composition of flavonoids in fresh herbs and calculation of flavonoid intake by use of herbs in traditional Danish dishes. Food Chem 2001; 73: 245-250.
76. Wang H, Provan GJ, Helliwell K. Determination of rosmarinic acid and caffeic acid in aromatic herbs by HPLC. Analytical, Nutritional and Clinical Methods 2004: 87: 307-311.
77. Diego MA, Jones NA, Field T, Hernandez-Reif M, Schanberg S, Kuhn C, et al. Aromatherapy positively affects mood, EEG patterns of alertness and math computations. Int J Neurosci 1998; 96: 217-24.
78. Moss M, Cook J, Wesnes K, Duckett P. Aromas of Rosemary and Lavender essential oils differentially affect cognition and mood in healthy adults. Int J Neurosci 2003; 113: 15-38.
79. Lazareno S, Popham A, Birdsall NJ. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors. J Mol Neurosci 2002; 19: 123-127.
80. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Rev 2003; 41: 268-287.
81. Carey GJ, Billard W, Binch H 3rd, Cohen-Williams M, Crosby G, Grzelak M, et al. SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur J Pharmacol 2001; 431: 189-200.
82. Ferreira AR, Furstenau L, Blanco C, Kornisiuk E, Sanchez G, Daroit D et al. Role of hippocampal M1 and M4 muscarinic receptor subtypes in memory consolidation in the rat. Pharmacol Biochem Behav 2003; 74: 411-415.
83. Levin ED, Bradley A, Addy N, Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 2002; 109: 757-65.
84. Chapouthier G, Venault P. GABA-A receptor complex and memory processes. Curr Top Med Chem 2002; 2: 841-51.
85. Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003; 64(Suppl 3): 28-35.
86. Santos-Gomes PC, Seabra RM, Andrade PB, Fernandes-Ferreira M. Phenolic antioxidant compounds produced by in vitro shoots of sage. Plant Sci 2002; 162: 981-987.
87. Putievsky E, Ravid U, Dudai N. The influence of season and harvest frequency on essential oil and herbal yields from a pure clone of sage (Salvia officinalis) grown under cultivated conditions. J Nat Prod 1986; 49: 326-329.
88. Bellomaria B, Arnold N, Valentini G, Arnold HJ. Contribution to the study of the essential oils from three species of Salvia growing wild in the eastern mediterranean region. J Essent Oil Res 1992; 4: 607-614.
89. Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr Pharm Design 2004; 10(25): 3167-75.
90. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Design 2004; 10(3): 261-4.
91. Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Design 2004; 10(25): 3177-84.